ELI LILLY AND COMPANY Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
ELI LILLY AND COMPANY (LLY) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of $72.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-05
- ELI LILLY AND COMPANY other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was $72.00M, a 22.03% increase year-over-year.
- ELI LILLY AND COMPANY other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was $47.00M, a 91.41% decline year-over-year.
- ELI LILLY AND COMPANY other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $326.40M.
- ELI LILLY AND COMPANY other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $509.70M, a 391.51% increase year-over-year.
- ELI LILLY AND COMPANY other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $1.44B, a 28740.00% increase from fiscal 2024.
- ELI LILLY AND COMPANY other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $5.00M.
- ELI LILLY AND COMPANY other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was -$482.00M, a 196.69% decline from fiscal 2022.
- ELI LILLY AND COMPANY other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was $498.50M, a 76.85% decline from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month as first filed | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month as first filed | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $72.00M 10-Q · filed 2026-08-05 | $119.00M 10-Q · filed 2026-08-05 | $445.40M derived: sum of 3 quarters · filed 2026-08-05 | $955.10M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $47.00M 10-Q · filed 2026-04-30 | $373.40M derived: sum of 2 quarters · filed 2026-04-30 | $883.10M derived: sum of 3 quarters · filed 2026-04-30 | $942.10M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | $326.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $836.10M derived: sum of 2 quarters · filed 2026-02-12 | $895.10M derived: sum of 3 quarters · filed 2026-08-05 | $1.44B 10-K · filed 2026-02-12 | |||
| 2025-09-30 | $509.70M 10-Q · filed 2025-10-30 | $568.70M derived: sum of 2 quarters · filed 2026-08-05 | $1.12B 10-Q · filed 2025-10-30 | $1.07B derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $59.00M 10-Q · filed 2026-08-05 | $58.60M 10-Q · filed 2025-08-07 | $606.00M 10-Q · filed 2026-08-05 | $605.90M 10-Q · filed 2025-08-07 | $558.80M derived: sum of 3 quarters · filed 2026-08-05 | $662.50M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $547.00M 10-Q · filed 2026-04-30 | $547.30M 10-Q · filed 2025-05-01 | $499.80M derived: sum of 2 quarters · filed 2026-04-30 | $603.50M derived: sum of 3 quarters · filed 2026-04-30 | $524.50M derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2024-12-31 | -$47.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $56.50M derived: sum of 2 quarters · filed 2026-02-12 | -$22.50M derived: sum of 3 quarters · filed 2026-02-12 | $5.00M 10-K · filed 2026-02-12 | $5.10M 10-K · filed 2025-02-19 | ||
| 2024-09-30 | $103.70M 10-Q · filed 2025-10-30 | $24.70M derived: sum of 2 quarters · filed 2025-10-30 | $52.20M 10-Q · filed 2025-10-30 | -$489.50M derived: sum of 4 quarters · filed 2026-02-12 | |||
| 2024-06-30 | -$79.00M 10-Q · filed 2025-08-07 | -$51.50M 10-Q · filed 2025-08-07 | -$593.20M derived: sum of 3 quarters · filed 2026-02-12 | -$589.40M derived: sum of 4 quarters · filed 2026-02-12 | |||
| 2024-03-31 | $27.50M 10-Q · filed 2025-05-01 | -$514.20M derived: sum of 2 quarters · filed 2026-02-12 | -$510.40M derived: sum of 3 quarters · filed 2026-02-12 | -$521.80M derived: sum of 4 quarters · filed 2026-02-12 | |||
| 2023-12-31 | -$541.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$537.90M derived: sum of 2 quarters · filed 2026-02-12 | -$549.30M derived: sum of 3 quarters · filed 2026-02-12 | -$482.00M 10-K · filed 2026-02-12 | -$482.40M 10-K · filed 2024-02-21 | ||
| 2023-09-30 | $3.80M 10-Q · filed 2024-10-30 | -$7.60M derived: sum of 2 quarters · filed 2024-10-30 | $59.70M 10-Q · filed 2024-10-30 | $510.90M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-06-30 | -$11.40M 10-Q · filed 2024-08-08 | $55.90M 10-Q · filed 2024-08-08 | $507.10M derived: sum of 3 quarters · filed 2025-02-19 | $499.00M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-03-31 | $67.30M 10-Q · filed 2024-04-30 | $518.50M derived: sum of 2 quarters · filed 2025-02-19 | $510.40M derived: sum of 3 quarters · filed 2025-02-19 | $448.00M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2022-12-31 | $451.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $443.10M derived: sum of 2 quarters · filed 2025-02-19 | $380.70M derived: sum of 3 quarters · filed 2025-02-19 | $498.50M 10-K · filed 2025-02-19 | |||
| 2022-09-30 | -$8.10M 10-Q · filed 2023-11-02 | -$70.50M derived: sum of 2 quarters · filed 2023-11-02 | $47.30M 10-Q · filed 2023-11-02 | ||||
| 2022-06-30 | -$62.40M 10-Q · filed 2023-08-08 | $55.40M 10-Q · filed 2023-08-08 | |||||
| 2022-03-31 | $117.80M 10-Q · filed 2023-04-27 | ||||||
| 2021-12-31 | $2.15B 10-K · filed 2024-02-21 | ||||||
| 2020-12-31 | $27.20M 10-K · filed 2023-02-22 | ||||||
| 2018-12-31 | $72.60M 8-K · filed 2019-10-24 | ||||||
| 2017-12-31 | -$465.60M derived: 8-K 12 month − 10-Q 9 month · filed 2019-10-24 | -$300.10M derived: sum of 2 quarters · filed 2019-10-24 | -$10.70M derived: sum of 3 quarters · filed 2019-10-24 | $199.00M 8-K · filed 2019-10-24 | |||
| 2017-09-30 | $165.50M 10-Q · filed 2018-11-06 | $454.90M derived: sum of 2 quarters · filed 2018-11-06 | $664.60M 10-Q · filed 2018-11-06 | ||||
| 2017-06-30 | $289.40M 10-Q · filed 2018-07-25 | $499.10M 10-Q · filed 2018-07-25 | |||||
| 2017-03-31 | $209.70M 10-Q · filed 2018-04-27 | ||||||
| 2016-12-31 | -$693.30M 8-K · filed 2019-10-24 | ||||||
| 2015-12-31 | -$588.90M 10-K · filed 2018-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |